BioInvent International Valuation

Is BINV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BINV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BINV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BINV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BINV?

Key metric: As BINV barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for BINV. This is calculated by dividing BINV's market cap by their current book value.
What is BINV's PB Ratio?
PB Ratio	2.9x
Book	SEK 1.00b
Market Cap	SEK 2.91b

BINV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	51.1x
Enterprise Value/EBITDA	-4.4x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does BINV's PB Ratio compare to its peers?

The above table shows the PB ratio for BINV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.2x
PROB Probi	2.9x	62.0%	SEK 4.0b
DMYD B Diamyd Medical	9.3x	-10.3%	SEK 1.4b
XSPRAY Xspray Pharma	2.5x	134.8%	SEK 1.4b
DVYSR Devyser Diagnostics	6.2x	119.5%	SEK 2.2b
BINV BioInvent International	2.9x	108.6%	SEK 2.9b

Price-To-Book vs Peers: BINV is good value based on its Price-To-Book Ratio (2.9x) compared to the peer average (5.2x).

Price to Book Ratio vs Industry

How does BINV's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 Companies	Price / Book	Estimated Growth	Market Cap
EXPRS2 ExpreS2ion Biotech Holding	0.6x	-11.9%	US$3.65m
SCOL Scandion Oncology	0.4x	69.7%	US$1.51m
CYXO Cyxone	0.4x	n/a	US$1.08m
DIABIO Diagonal Bio	0.4x	n/a	US$1.08m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: BINV is expensive based on its Price-To-Book Ratio (2.9x) compared to the Swedish Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is BINV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BINV PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.9x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BINV's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

PMD Device Solutions

SEK 34.0m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.31

2.3%

n/a

AstraZeneca

UK£164.2b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,472.00

4.1%

9.8%

Corline Biomedical

SEK 132.0m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.14

-7.0%

-54.0%